| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
IC50: 10 nM (B. theta rBSH), 80 nM (B. longum rBSH)[1]
|
|---|---|
| ln Vitro |
In bacterial cultures, AAA-10 (100 μM; 24 h) formic suppresses BSH activity; the IC50 values for Gram-positive and Gram-negative bacteria are 901 nM and 74 nM, respectively[1]. Human feces' glycochenodeoxycholic acid-d4 or taurocholic acid-d4 substrates are significantly inhibited from deconjugating by AAA-10(20 μM; 2 h) formic acid[1].
|
| ln Vivo |
AAA-10 (30 mg/kg; five days of oral gavage) Deoxycholic acid (DCA) and lithocholic acid (LCA) abundances in mice feces are reduced by formic acid beginning on day 2–5[1]. Formic AAA-10 (30 mg/kg) exhibits minimal gut permeability and high colonic exposure[1].
|
| Animal Protocol |
Animal/Disease Models: 10-11 weeks old male C57Bl/6J mice[1]
Doses: 30 mg/kg Route of Administration: Orally gavaged one time/day for 5 days Experimental Results: diminished the abundances of DCA and LCA in mice feces starting in day 2-5. Displayed high colonic exposure and low gut permeability. |
| References |
| Molecular Formula |
C26H43FO7S
|
|---|---|
| Related CAS # |
AAA-10;2758171-70-7
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~16.67 mg/mL (~32.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (3.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
